Navigation Links
FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
Date:6/1/2010

SILVER SPRING, Md., June 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the United States with osteoporosis are women. One out of every two women over age 50 will break a bone in their lifetime due to osteoporosis.

People with osteoporosis at high risk for fracture include those that have had an osteoporotic fracture, or have multiple risk factors for fracture; or those who have failed or are intolerant to other available osteoporosis therapy. Prolia works to decrease the destruction of bone and increase bone mass and strength. An injection of Prolia is recommended once every six months.

"Due to its prevalence, osteoporosis is a serious concern to public health," said Julie Beitz, M.D., director of the FDA's Office of Drug Evaluation III. "The approval of Prolia provides another treatment option for postmenopausal women with osteoporosis who are susceptible to fractures."

The safety and efficacy of Prolia in the treatment of postmenopausal osteoporosis was demonstrated in a three-year, randomized, double-blind, placebo-controlled trial of 7,808 postmenopausal women ages 60 to 91 years. In the study, Prolia reduced the incidence of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis.

The most common side effects reported with Prolia include back pain, pain in the extremities, musculoskeletal pain, high cholesterol levels, and urinary bladder infections. Serious adverse reactions include hypocalcaemia (low calcium levels in the blood), serious infections, including infections of the skin, and dermatologic reactions such as dermatitis, rashes, and eczema.

Prolia causes significant suppression of bone turnover and this suppression may contribute to the occurrence of osteonecrosis of the jaw, a severe bone disease that affects the jaw, atypical fractures, and delayed fracture healing.

Prolia was approved with a risk evaluation and mitigation strategy (REMS) that includes a Medication Guide for patients and communications to health care providers that explains the risks and benefits of the drug.

Prolia is manufactured by Amgen Manufacturing Limited, a subsidiary of Thousand Oaks, Calif.-based Amgen Inc.

For more information

Fast Facts on Osteoporosis – National Institute of Arthritis and Musculoskeletal and Skin Diseases

http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/osteoporosis_ff.asp

Media Inquiries: Elaine Gansz Bobo, 301.796.7567, elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves New Treatment for Late-Onset Pompe Disease
2. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
3. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
4. FDA Approves New Combination Product Oral Contraceptive
5. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
6. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
7. FDA Approves New Device for Adults with Severe and Persistent Asthma
8. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
9. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
10. FDA Approves First Totally Implanted Hearing System
11. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/29/2017)... May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... which enables the functional selection of stem cells, today ... the first quarter ended March 31 st , 2017. ... accomplishments in the first quarter of 2017," said Dr. ... we announced the treatment of the first blood cancer ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, recognized ... medical devices for pressure ulcer prevention, will unveil ... Association of Critical Care Nurses, National Teaching Institute ... The Leaf Patient Monitoring System is ... the hospital environment.  The system seamlessly tracks patient ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that ... the risk of visual loss in these patients. , But how often do ophthalmologists ... smoking cessation to patients at risk of or with early symptoms of AMD? A ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when it ... it, and some people don't like it at all. FindaTopDoc took a look at ... Erotic literature can give readers a taste of their deepest, darkest fantasies and has ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ( ... Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people than ... Biggert-Waters Act was enacted to reflect the actual risk in flood zone areas ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, a ... in the greater Chicago metropolitan area, is embarking on a charity drive in ... Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the oldest ...
Breaking Medicine News(10 mins):